This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
HIV-1-infection

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

Sponsored by Shanghai Public Health Clinical Center

About this trial

Last updated 2 years ago

Study ID

Zadaxin-HIV

Status

Completed

Type

Interventional

Phase

Early Phase 1

Placebo

No

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 3 years ago

What is this trial about?

The purpose of this study is to evaluate the safety and efficacy of Zadaxin® in the treatment of HIV-positive patients with immune reconstitution disorders. Researchers previously used Zadaxin® (Thymosin α-1, Tα1) as an immune adjuvant for people infected with HIV-1 and found that Tα1 and Interferon-α (IFN-α) have a synergistic effect in immune enhancement. In addition, studies have found that the triple combination of Tα1, IFN-α and Zidovudine has better tolerability, safety and efficacy. After treatment, patients have lower HIV RNA and more stable high CD4+ T cell counts. In addition, extensive studies on the administration of Tα1 in thymectomized mice have demonstrated its ability to promote immune reconstitution. The researchers hypothesized that Zadaxin® has a better therapeutic effect on HIV-positive patients with immune reconstitution disorders, can increase the CD4+T cell count, reduce the viral load, and has better safety.

What are the participation requirements?

Yes

Inclusion Criteria

- Age 18-65 years old;

- HIV serology is positive;

- Volunteer to participate;

- CD4+T cell count >100 and <350 cells/mm3;

- People who have received HAART treatment and the viral load is undetected for at least 2 years, but have immune reconstitution disorder;

- Without active opportunistic infection;

No

Exclusion Criteria

- History of allergy or contraindications to Zadaxin;

- Skin basal cell carcinoma, cervical carcinoma in situ or other concurrent tumors other than Kaposi's sarcoma;

- The expected survival time is less than 1 year;

- Women of childbearing age have a positive pregnancy test;

- Major heart disease or central nervous system disease or other nervous system abnormalities;

- ACTG-AIDS dementia syndrome staging score> 0.5;

- Organ transplantation;

- Received chemotherapy and radiotherapy for malignant tumors within 6 months;

- Known immunomodulators (such as systemic steroids, interferons, interleukins) or other immunotherapy within 30 days before the start of the study;

- Blood transfusion within 30 days before the start of the study;

- Have a history of iritis, endophthalmitis, scleritis or retinitis;

- Within 30 days before the screening assessment, accept any experimental treatment for HIV-positive patients with or without symptoms of infection;

- Drug abuse;

- The doctor's decision is that participation in the trial is not in the patient's best interests, or any situation that does not allow safe compliance with the protocol.

Locations

Location

Status

BESbswy